The biologicals market is entering the 2026 season with a defining paradox: more products are reaching the market and more agricultural companies are investing in the category, yet trust remains the biggest barrier to wider adoption. A January 2026 survey of 90 U.S. agricultural industry participants found that 39% identified a lack of trust in product performance as the leading obstacle. The finding matters because biologicals have moved beyond a niche discussion. From U.S. corn and soybeans to Brazilian row crops and Latin American fruit and vegetable production, growers increasingly want to know not only whether a technology is innovative, but whether it performs consistently and delivers an economic return.

There is an important distinction behind the numbers. This was not a direct farmer survey. About 86% of respondents were agricultural retailers, cooperatives and crop consultants, while 8% represented fertilizer producers or suppliers and 6% manufacturers or formulators. The Midwest accounted for 43% of responses, and the businesses surveyed primarily served corn, soybeans and wheat. That makes the findings particularly useful for understanding what the people recommending and selling agricultural inputs are hearing as biological products move deeper into mainstream crop programs.

Bioinputs

Biologicals Are Gaining Ground, but One Major Barrier Is Still Holding Farmers Back

Trust, Not Price, Is Emerging as the Bigger Challenge

The most revealing number may be the gap between performance concerns and price concerns. While 39% cited a lack of trust in biological product performance as the biggest adoption barrier, only 19% pointed to price. Another 16% said growers believe conventional products perform better, while the remaining responses included handling and storage concerns, potential impacts on seller profitability and regulatory issues. Trust improved slightly from the previous survey, but it remains by far the largest obstacle facing the category.

What Is Holding Back Wider Biological Adoption?

The challenge goes beyond whether a product "works." Biological performance can interact with soil conditions, temperature, moisture, fertility, crop development and other environmental variables, increasing the importance of replicated field data and clear recommendations about where a product is most likely to deliver value. For growers facing tight margins, that distinction matters. A promising trial or isolated yield response may generate interest, but repeatability across environments and seasons is what can turn experimentation into routine purchasing.

At the same time, the market data show that skepticism is not stopping commercialization. Biostimulants accounted for 50% of biological products sold by respondents, compared with 32% for biofertilizers and 18% for biopesticides. When respondents were asked which categories their businesses offered, 84% reported selling biostimulants, 54% biofertilizers and 30% biopesticides. The numbers suggest the conversation is moving beyond whether biologicals belong in agriculture toward a more demanding question: which products can earn a permanent place in the crop program?

Biologicals Already Reaching U.S. Crop Programs

Perhaps the clearest indication of where the market is heading is how biologicals are actually being used. Ninety-eight percent of respondents said growers use biological products as supplements to conventional products, while only 2% said they are used as standalone replacements. That challenges the idea that biologicals will quickly displace synthetic crop protection or traditional fertility programs. Instead, the emerging model is one of integration, with biological, chemical and nutritional technologies combined according to crop, environment, production objective and risk.

How Growers Are Using Biologicals

From U.S. Row Crops to Latin American Specialty Crops

The trust question becomes even more significant when viewed beyond the U.S. market. In July 2026, the Food and Agriculture Organization of the United Nations (FAO) reported that Latin America and the Caribbean is the world's fastest-growing region for bioinput use, expanding at more than 10% annually. FAO estimated global adoption of biostimulants, biofertilizers and biocontrol products at about 38% of farmers, while adoption in Brazil reached 67%. Importantly, FAO also emphasized that the economics vary by crop, soil, agroecological conditions, production scale and technology-reinforcing the argument that biological performance cannot be reduced to a single universal ROI figure.

Brazil provides one of the clearest examples of biologicals moving toward scale. The country's Ministry of Agriculture reported 162 biological and related products registered in 2025, a record for its historical series. Brazil is particularly relevant to the U.S. market because both countries operate enormous corn and soybean systems, but Brazil's biological ecosystem has expanded alongside a national bioinputs policy and a specific regulatory framework. The market is therefore becoming an important reference point for manufacturers looking at how biological technologies can move from individual trials into large-scale commercial agriculture.

Argentina illustrates another side of the market. Biological inoculants already have a long history in row crops, particularly soybeans, but recent research by INTA found significant activity outside broad-acre agriculture. A national assessment released in September 2026 identified 92 experiences involving biological preparations, with 75% associated with intensive horticulture. Researchers also identified demand for standardized protocols, laboratory analysis and training. Those needs closely mirror the trust challenge identified in the U.S.: biological innovation ultimately needs reproducible evidence and clear technical guidance to scale.

Chile, Colombia and Mexico further broaden the picture. In Chile, INIA and the country's agricultural authority worked with growers in the O'Higgins region during 2026 on bioinputs, on-farm biofactories and regulations covering biostimulants and non-synthetic pesticides, including work connected with cucurbit production. In Colombia, the ICA trained pineapple growers on bioinput preparation and use and has also worked with cacao producers. Mexico's SENASICA, meanwhile, operates a national biological control reference center that evaluates microorganisms and other biological agents through laboratory, greenhouse and field testing.

Biologicals Across Different Latin American Production Systems

Peru adds another dimension because its agricultural model is strongly connected to high-value export crops, including blueberries, table grapes, avocados, citrus and vegetables. In these systems, the value proposition surrounding biologicals can extend beyond yield alone. Pest management, crop quality, production protocols and access to demanding international markets can all influence technology decisions. This makes specialty crops an important testing ground for the next generation of biological products, although the available evidence does not support applying the U.S. survey's adoption percentages directly to Peruvian growers.

For U.S. companies, the Latin American experience matters for another reason: the same biological technology may be evaluated under dramatically different production environments. A microbial product used in Midwestern corn faces different soils, temperatures, application windows and economics than a biological used in Brazilian soybeans, Argentine vegetables, Chilean fruit or Colombian pineapple. As companies expand internationally, generating local data may therefore become just as important as building larger product portfolios.

Back in the U.S., the commercial signal remains decidedly expansionary. Eighty percent of survey respondents expect to increase the number of biological products they sell over the next year, while 16% expect to maintain their current offering and only 4% anticipate reducing it. That is slightly below the 82% that planned expansion in the previous survey, but it still points to a market where retailers are adding biological technologies even as scrutiny around performance increases.

U.S. Retailers Still Plan to Expand Their Biological Portfolios

That may ultimately define the next phase of the biologicals market. Farmers are not necessarily rejecting biologicals; they are raising the standard of proof required before investing in them. For manufacturers and ag retailers, the competitive advantage may increasingly come not from launching the largest number of products, but from demonstrating where a technology works, how consistently it performs, how it fits alongside conventional crop protection and fertility programs, and-most importantly-what measurable economic value it delivers to the farm.